全部 标题 作者
关键词 摘要

A Combination of Tanacetum parthenium, Griffonia simplicifolia and Magnesium (Aurastop) as Symptomatic Acute Treatment for Migraine Aura: A Retrospective Cohort Study

DOI: 10.4236/oalib.1103660, PP. 1-9

Subject Areas: Neurology

Keywords: Migraine Aura, Cortical Spreading Depression, NMDA Receptor

Full-Text   Cite this paper   Add to My Lib


Background: effective treatments for migraine aura and related symptoms are not yet well established. In the last years, several herbal and/or nutraceutical preparations have been proposed as potential treatment. We report the results of a retrospective analysis on the synergistic effect of three nutraceutical components (Tanacetum parthenium, Griffonia simpliciofila and Magnesium, Aurastop) as symptomatic treatment of migraine aura and related symptoms. Method: Forty-nine subjects with headache with aura were recruited from the headache Center of the Istituto Clinico Citta’ di Brescia to enter the studied that consist to treat the first 3 aura attacks as usual and the next 3 taking a tablet of Aurastop at the beginning of the aura phenomena. They had to describe aura and headache characteristics of previous three attacks (t1) and the modification of these parameters with the assumption of Aurastop for the following three attacks (t2). Results: A significant reduction (>50%) in aura duration (t1 = 33.6 ± 10.1 minutes vs. t2 = 9.4 ± 6.2 minutes, p < 0.01 FWER corrected) as well as in overall disability (median [interquartile range]) (t1 = 5[4 - 5] vs. t2 = 1[1 - 2], p < 0.01 FWER corrected) was evident. Furthermore, modification of aura type as well as a series of parameters more related to headache (number of headache attacks, duration, intensity, utilization of analgesics and response to symptomatic treatment) was influenced by Aurastop utilization (p < 0.01 FWER corrected). No significant adverse effects were recorded after the assumption of Aurastop. Conclusions: the combined and synergistic effect of Tanacetum parthenium, Griffonia simpliciofila and Magnesium (Aurastop) highlights the idea that symptomatic treatment potentially modulating cortical spreading depression could deserve attention to mitigate aura and related symptoms (migraine as well as long-lasting discomfort). Further blinded, placebo-controlled studies on larger groups are warranted.

Cite this paper

Zavarise, P. and Volta, G. D. (2017). A Combination of Tanacetum parthenium, Griffonia simplicifolia and Magnesium (Aurastop) as Symptomatic Acute Treatment for Migraine Aura: A Retrospective Cohort Study. Open Access Library Journal, 4, e3660. doi: http://dx.doi.org/10.4236/oalib.1103660.


[1]  Lipton, R.B., Bigal, M.E., Diamond, M., Freitag, F., Reed, M.L. and Stewart, W.F. (2007) Migraine Prevalence, Disease Burden, and the Need for Preventive Therapy. Neurology, 68, 343-349.
[2]  Bloudek, L.M., Stokes, M., Buse, D.C., Wilcox, T.K., Lipton, R.B., Goadsby, P.J., et al. (2012) Cost of Healthcare for Patients with Migraine in Five European Countries: Results from the International Burden of Migraine Study (IBMS). The Journal of Headache and Pain, 13, 361-378.
[3]  Steiner, T.J., Birbeck, G.L., Jensen, R., Katsarava, Z., Martelletti, P. and Stovner, L.J. (2011) The Global Campaign, World Health Organization and Lifting the Burden: Collaboration in Action. The Journal of Headache and Pain, 12, 273-274.
[4]  Russell, M.B., Rasmussen, B.K., Thorvaldsen, P. and Olesen, J. (1995) Prevalence and Sex-Ratio of the Subtypes of Migraine. International Journal of Epidemiology, 24, 612-618.
[5]  Charles, A. and Hansen, J.M. (2015) Migraine Aura: New Ideas about Cause, Classification, and Clinical Significance. Current Opinion in Neurology, 28, 255-260.
[6]  Petrusic, I. and Zidverc-Trajkovic, J. (2014) Cortical Spreading Depression: Origins and Paths as Inferred from the Sequence of Events during Migraine Aura. Functional Neurology, 29, 207-212.
[7]  Leao, A.A. (1947) Further Observations on the Spreading Depression of Activity in the Cerebral Cortex. Journal of Neurophysiology, 10, 409-414.
[8]  Hadjikhani, N., Sanchez Del Rio, M., Wu, O., Schwartz, D., Bakker, D., Fischl, B., et al. (2001) Mechanisms of Migraine Aura Revealed by Functional MRI in Human Visual Cortex. Proceedings of the National Academy of Sciences of the United States of America, 98, 4687-4692.
[9]  Thorlund, K., Mills, E.J., Wu, P., Ramos, E., Chatterjee, A., Druyts, E., et al. (2014) Comparative Efficacy of Triptans for the Abortive Treatment of Migraine: A Multiple Treatment Comparison Meta-Analysis. Cephalalgia: An International Journal of Headache, 34, 258-267.
[10]  Afridi, S.K., Giffin, N.J., Kaube, H. and Goadsby, P.J. (2013) A Randomized Controlled Trial of Intranasal Ketamine in Migraine with Prolonged Aura. Neurology, 80, 642-647.
[11]  Hauge, A.W., Asghar, M.S., Schytz, H.W., Christensen, K. and Olesen, J. (2009) Effects of Tonabersat on Migraine with Aura: A Randomised, Double-Blind, Placebo-Controlled Crossover Study. The Lancet Neurology, 8, 718-723.
[12]  Rozen, T.D. (2003) Aborting a Prolonged Migrainous Aura with Intravenous Pro- chlorperazine and Magnesium Sulfate. Headache, 43, 901-903.
[13]  Rajapakse, T. and Pringsheim, T. (2016) Nutraceuticals in Migraine: A Summary of Existing Guidelines for Use. Headache, 56, 808-816.
[14]  Diener, H.C., Pfaffenrath, V., Schnitker, J., Friede, M. and Henneicke-von Zepelin, H.H. (2005) Efficacy and Safety of 6.25 mg t.i.d. Feverfew CO2-Extract (MIG-99) in Migraine Prevention—A Randomized, Double-Blind, Multicentre, Placebo-Con- trolled Study. Cephalalgia: An International Journal of Headache, 25, 1031-1041.
[15]  Tassorelli, C., Greco, R., Morazzoni, P., Riva, A., Sandrini, G. and Nappi, G. (2005) Parthenolide Is the Component of Tanacetum parthenium That Inhibits Nitroglycerin-Induced Fos Activation: Studies in an Animal Model of Migraine. Cephalalgia: An International Journal of Headache, 25, 612-621.
[16]  Chauvel, V., Vamos, E., Pardutz, A., Vecsei, L., Schoenen, J. and Multon, S. (2012) Effect of Systemic Kynurenine on Cortical Spreading Depression and Its Modulation by Sex Hormones in Rat. Experimental Neurology, 236, 207-214.
[17]  Sun-Edelstein, C. and Mauskop, A. (2009) Role of Magnesium in the Pathogenesis and Treatment of Migraine. Expert Review of Neurotherapeutics, 9, 369-379.
[18]  Website. The International Classification of Headache Disorders. 3rd Edition (Beta Version).
[19]  Farrar, J.T., Young Jr., J.P., LaMoreaux, L., Werth, J.L. and Poole, R.M. (2001) Clinical Importance of Changes in Chronic Pain Intensity Measured on an 11-Point Numerical Pain Rating Scale. Pain, 94, 149-158.
[20]  Bender, R. and Lange, S. (2001) Adjusting for Multiple Testing—When and How? Journal of Clinical Epidemiology, 54, 343-349.
[21]  Viana, M., Linde, M., Sances, G., Ghiotto, N., Guaschino, E., Allena, M., et al. (2016) Migraine Aura Symptoms: Duration, Succession and Temporal Relationship to Headache. Cephalalgia: An International Journal of Headache, 36, 413-421.
[22]  Matei, D., Constantinescu, V., Corciova, C., Ignat, B., Matei, R. and Popescu, C.D. (2015) Autonomic Impairment in Patients with Migraine. European Review for Medical and Pharmacological Sciences, 19, 3922-3927.
[23]  Petrusic, I., Zidverc-Trajkovic, J., Podgorac, A. and Sternic, N. (2013) Underestimated Phenomena: Higher Cortical Dysfunctions during Migraine Aura. Cephalalgia: An International Journal of Headache, 33, 861-867.
[24]  Hansen, J.M., Baca, S.M., Vanvalkenburgh, P. and Charles, A. (2013) Distinctive Anatomical and Physiological Features of Migraine Aura Revealed by 18 Years of Recording. Brain, 136, 3589-3595.
[25]  Lampl, C., Katsarava, Z., Diener, H.C. and Limmroth, V. (2005) Lamotrigine Reduces Migraine Aura and Migraine Attacks in Patients with Migraine with Aura. Journal of Neurology, Neurosurgery, and Psychiatry, 76, 1730-1732.
[26]  Sahler, J., Bernard, J.J., Spinelli, S.L., Blumberg, N. and Phipps, R.P. (2011) The Feverfew Plant-Derived Compound, Parthenolide Enhances Platelet Production and Attenuates Platelet Activation through NF-κB Inhibition. Thrombosis Research, 127, 426-434.
[27]  Materazzi, S., Benemei, S., Fusi, C., Gualdani, R., De Siena, G., Vastani, N., et al. (2013) Parthenolide Inhibits Nociception and Neurogenic Vasodilatation in the Trigeminovascular System by Targeting the TRPA1 Channel. Pain, 154, 2750-2758.
[28]  Ho, T.W., Ferrari, M.D., Dodick, D.W., Galet, V., Kost, J., Fan, X., et al. (2008) Efficacy and Tolerability of MK-0974 (Telcagepant), a New Oral Antagonist of Calcitonin Gene-Related Peptide Receptor, Compared with Zolmitriptan for Acute Migraine: A Randomised, Placebo-Controlled, Parallel-Treatment Trial. The Lancet, 372, 2115-2123.
[29]  Curto, M., Lionetto, L., Negro, A., Capi, M., Fazio, F., Giamberardino, M.A., et al. (2015) Altered Kynurenine Pathway Metabolites in Serum of Chronic Migraine Patients. The Journal of Headache and Pain, 17, 47.
[30]  Mody, I., Lambert, J.D. and Heinemann, U. (1987) Low Extracellular Magnesium Induces Epileptiform Activity and Spreading Depression in Rat Hippocampal Slices. Journal of Neurophysiology, 57, 869-888.
[31]  Teigen, L. and Boes, C.J. (2015) An Evidence-Based Review of Oral Magnesium Supplementation in the Preventive Treatment of Migraine. Cephalalgia: An International Journal of Headache, 35, 912-922.
[32]  Begon, S., Pickering, G., Eschalier, A., Mazur, A., Rayssiguier, Y. and Dubray, C. (2001) Role of Spinal NMDA Receptors, Protein Kinase C and Nitric Oxide Synthase in the Hyperalgesia Induced by Magnesium Deficiency in Rats. British Journal of Pharmacology, 134, 1227-1236.


comments powered by Disqus